Aliskiren/amlodipine/hydrochlorothiazide
The drug combination aliskiren/amlodipine/hydrochlorothiazide (INNs, trade name Amturnide) is an antihypertensive approved in the United States on 21 December 2010.[1][2]
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Amlodipine | Calcium channel blocker |
| Hydrochlorothiazide | Diuretic |
| Clinical data | |
| Trade names | Amturnide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| KEGG | |
| Chemical and physical data | |
| Formula | C57H86Cl2N8O15S2 |
| Molar mass | 1258.38 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
References
- Amturnide approval letter. U.S. Food and Drug Administration (FDA).
- "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020. Lay summary (PDF).
External links
- "Aliskiren mixture with amlodipine and hydrochlorothiazide". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.